Ludger Johannes Selected Research

Shiga Toxin (Shigella Toxin)

1/2022	High-Relaxivity Molecular MRI Contrast Agent to Target Gb3-Expressing Cancer Cells.
1/2022	Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.
5/2021	The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery-The GL-Lect Hypothesis.
10/2020	Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit.
10/2019	Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism.
12/2018	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.
1/2017	Induction of resident memory T cells enhances the efficacy of cancer vaccine.
1/2016	Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
11/2015	Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry.
6/2015	Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ludger Johannes Research Topics

Disease

36	Neoplasms (Cancer) 10/2022 - 03/2005
5	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2006
4	Infections 10/2022 - 01/2010
4	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2006
4	Cholera 01/2015 - 03/2005
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2017 - 01/2013
3	Adenocarcinoma 01/2016 - 07/2006
3	Carcinoma (Carcinomatosis) 01/2016 - 09/2012
2	Lung Neoplasms (Lung Cancer) 01/2021 - 02/2013
2	Hemolytic-Uremic Syndrome 10/2020 - 10/2019
2	Carcinogenesis 01/2020 - 01/2020
2	Breast Neoplasms (Breast Cancer) 12/2018 - 08/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016 - 10/2011
1	Virus Diseases (Viral Diseases) 10/2022
1	Communicable Diseases (Infectious Diseases) 10/2022
1	Osteosarcoma (Osteogenic Sarcoma) 01/2022
1	Neuroinflammatory Diseases 10/2021
1	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 10/2021
1	Acute Kidney Injury (Acute Renal Failure) 01/2019
1	Muscular Diseases (Myopathy) 01/2019
1	Rhabdomyolysis 01/2019
1	Colonic Neoplasms (Colon Cancer) 12/2018
1	Melanoma (Melanoma, Malignant) 12/2018
1	Inflammation (Inflammations) 01/2018
1	Neurodevelopmental Disorders 01/2018
1	Bacterial Infections (Bacterial Infection) 12/2016
1	Ovarian Neoplasms (Ovarian Cancer) 10/2016
1	Stomach Neoplasms (Stomach Cancer) 01/2016
1	Squamous Cell Carcinoma of Head and Neck 06/2015
1	Lymphatic Metastasis 12/2014
1	Hematologic Neoplasms (Hematological Malignancy) 11/2011
1	Adenoma (Adenomas) 08/2008
1	Phototoxic Dermatitis (Phototoxicity) 02/2008

Drug/Important Bio-Agent (IBA)

20	Shiga Toxin (Shigella Toxin)IBA 01/2022 - 03/2005
13	GlycosphingolipidsIBA 01/2022 - 07/2006
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2005
7	VaccinesIBA 10/2022 - 09/2007
6	AntigensIBA 10/2022 - 05/2006
6	Cancer VaccinesIBA 01/2021 - 11/2011
5	globotriaosylceramide (globotriosylceramide)IBA 01/2020 - 11/2008
4	Contrast MediaIBA 01/2022 - 07/2006
3	LipidsIBA 05/2021 - 09/2012
3	GlycolipidsIBA 05/2021 - 11/2008
3	LigandsIBA 01/2020 - 02/2008
3	ClathrinIBA 01/2020 - 08/2005
3	Shiga Toxins (Vero Toxin)IBA 01/2020 - 03/2005
2	Immune Checkpoint InhibitorsIBA 10/2022 - 01/2013
2	Pharmaceutical PreparationsIBA 10/2021 - 11/2015
2	Glycoproteins (Glycoprotein)IBA 05/2021 - 01/2020
2	CarbohydratesIBA 01/2020 - 01/2018
2	Biological ProductsIBA 01/2020 - 01/2013
2	Peptides (Polypeptides)IBA 12/2018 - 08/2016
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2016 - 10/2011
2	Cytotoxins (Cytolysins)IBA 01/2016 - 11/2015
1	Immunoglobulin A (IgA)IBA 10/2022
1	Viral AntigensIBA 10/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	UDP-galactose-lactosylceramide alpha 1-4-galactosyltransferaseIBA 01/2022
1	Tamoxifen FDA LinkGeneric 10/2021
1	LectinsIBA 05/2021
1	globotetraosylceramideIBA 01/2020
1	Neutral GlycosphingolipidsIBA 01/2020
1	Virulence Factors (Pathogenicity Factors)IBA 10/2019
1	AlbuminsIBA 01/2019
1	AminoglycosidesIBA 01/2019
1	Muscle Proteins (Muscle Protein)IBA 01/2019
1	MyoglobinIBA 01/2019
1	Glucosylceramides (Glucocerebrosides)IBA 01/2019
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2019
1	MetalsIBA 12/2018
1	temsirolimus FDA Link 12/2018
1	Galectins (Galectin)IBA 01/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Interferon Type IIBA 12/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2016
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 08/2016
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 08/2016
1	LuciferasesIBA 06/2015
1	Estrogen ReceptorsIBA 12/2014
1	Biomarkers (Surrogate Marker)IBA 01/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2012
1	G(M1) GangliosideIBA 09/2012
1	Galectin 3 (LGALS3)IBA 09/2012
1	Cadherins (E-Cadherin)IBA 09/2012
1	IntegrinsIBA 09/2012
1	AutoantigensIBA 11/2011
1	HydrocarbonsIBA 01/2010
1	Bacterial ToxinsIBA 01/2010
1	GABA-A Receptors (GABA(A) Receptor)IBA 11/2008
1	4'-chlorodiazepamIBA 11/2008
1	Indicators and Reagents (Reagents)IBA 11/2008
1	BenzodiazepinesIBA 11/2008
1	CeramidesIBA 08/2008
1	Singlet OxygenIBA 02/2008

Therapy/Procedure

7	Immunotherapy 10/2022 - 02/2010
6	Therapeutics 10/2022 - 07/2006
2	Radiotherapy 10/2022 - 06/2015
1	Intravenous Injections 12/2014
1	Drug Therapy (Chemotherapy) 10/2011
1	Microbubbles 04/2011